MRI-guided STN DBS in Parkinson’s disease without microelectrode recording: efficacy and safety

T Foltynie,1 L Zrinzo,1,2 I Martinez-Torres,3 E Tripoliti,1 E Petersen,4 E Holl,1,5 I Aviles-Olmos,1 M Jahanshahi,1 M Hariz,1,6 P Limousin1

ABSTRACT

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a commonly employed therapeutic procedure for patients with Parkinson’s disease uncontrolled by medical therapies. This series describes the outcomes of 79 consecutive patients that underwent bilateral STN DBS at the National Hospital for Neurology and Neurosurgery between November 2002 and November 2008 using an MRI-guided surgical technique without microelectrode recording. Patients underwent immediate postoperative stereotactic MR imaging. The mean (SD) error in electrode placement was 1.3 (0.6) mm. There were no haemorrhagic complications. At a median follow-up period of 12 months, there was a mean improvement in the off-medication motor part of the Unified Parkinson’s Disease Rating Scale (UPDRS III) of 27.7 points (SD 13.8) equivalent to a mean improvement of 52% (p<0.0001). In addition, there were significant improvements in dyskinesia duration, disability and pain, with a mean reduction in on-medication dyskinesia severity (sum of dyskinesia duration, disability and pain from UPDRS IV) from 3.15 (SD 2.33) pre-operatively, to 1.56 (SD 1.92) post-operatively (p=0.0001). Quality of life improved by a mean of 5.5 points (median 7.9 points, SD 17.3) on the Parkinson’s disease Questionnaire 39 summary index. This series confirms that image-guided STN DBS without microelectrode recording can lead to substantial improvements in motor disability of well-selected PD patients with accompanying improvements in quality of life and most importantly, with very low morbidity.

In clinical practice, brain imaging can now be divided in two parts: the diagnostic neuroradiology and the preoperative stereotactic localisation procedure. The latter is part of the therapeutic procedure. It is the surgeon’s responsibility and should be closely integrated with the operation.” Lars Leksell1.

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an accepted surgical treatment for PD. PD is a chronic disabling motor complication of the illness despite optimal medical treatment. Before deciding on suitability for surgery, a brain MRI was obtained to exclude patients with advanced brain atrophy, white matter changes or other abnormality contraindicating surgery. Baseline neuropsychological tests identified patients with significant cognitive impairment and L-dopa equivalent doses calculated for each patient.7 An L-dopa challenge was performed to confirm drug responsiveness using the motor part of the Unified Parkinson’s Disease Rating Scale (UPDRS III). A numerical measure of L-dopa response was derived as follows: (Off UPDRS III – On UPDRS III score)/Off UPDRS III×100. The off-medication state was practically defined as an overnight period free of medication. Speech was assessed using the Assessment of Intelligibility for Dysarthric Speech.8 Patients were asked to complete the Parkinson's Disease Questionnaire 39 scale (PDQ39).9 The final decision regarding the appropriateness of STN DBS surgery for each patient was taken during a joint meeting of patient, immediate family, neurologist(s) and neurosurgeon(s).

Image acquisition and surgical procedure

Surgery was usually performed under local anaesthesia, in the off-medication condition, to allow clinical evaluation during electrode placement. If the patient was unable to tolerate prolonged periods off medication, surgery was performed under general anaesthesia (n=12). The STN was

MATERIAL AND METHODS

Patients

Seventy-nine consecutive patients underwent STN DBS at the National Hospital for Neurology and Neurosurgery between November 2002 and November 2008. All patients met UK Brain Bank criteria for the diagnosis of PD and suffered from disabling motor complications of the illness despite optimal medical treatment. Before deciding on surgery, a brain MRI was obtained to exclude patients with advanced brain atrophy, white matter changes or other abnormality contraindicating surgery. Baseline neuropsychological tests identified patients with significant cognitive impairment and L-dopa equivalent doses calculated for each patient.7 An L-dopa challenge was performed to confirm drug responsiveness using the motor part of the Unified Parkinson’s Disease Rating Scale (UPDRS III). A numerical measure of L-dopa response was derived as follows: (Off UPDRS III – On UPDRS III score)/Off UPDRS III×100. The off-medication state was practically defined as an overnight period free of medication. Speech was assessed using the Assessment of Intelligibility for Dysarthric Speech.8 Patients were asked to complete the Parkinson's Disease Questionnaire 39 scale (PDQ39).9 The final decision regarding the appropriateness of STN DBS surgery for each patient was taken during a joint meeting of patient, immediate family, neurologist(s) and neurosurgeon(s).

Image acquisition and surgical procedure

Surgery was usually performed under local anaesthesia, in the off-medication condition, to allow clinical evaluation during electrode placement. If the patient was unable to tolerate prolonged periods off medication, surgery was performed under general anaesthesia (n=12). The STN was
visualised in each patient using specifically selected pre-operative stereotactic MRI sequences following Leksell frame attachment (Elekta Instrument AB, Stockholm). Target selection for placement of the deepest contact was performed at the level of maximal rubral diameter (around 5 mm below the AC–PC plane) using commercially available planning software (FrameLink, Medtronic, Minneapolis). The STN was visualised as the hypointense signal lateral to the red nucleus. The entry point was defined at or behind the coronal suture to ensure a trajectory that would avoid sulci and the ventricular system. The exact entry and target point were subsequently modified to maintain a parenchymal trajectory while maximising the length of the trajectory within the visible STN hypointensity from the AC–PC to target level. This was best achieved by reformatting images along the planned trajectory. As a result, the final target point was often located a couple of millimetres posterolateral to the target point described by Bejjani et al. Since the sensorimotor STN is thought to occupy the supero-postero-lateral portion of the nucleus, this target point may bring the electrode trajectory closer to the desired functional target.

During surgery, brain shift was avoided in several ways. Minimal CSF loss was achieved by placing the 14-mm burr hole and 3–4 mm small dural opening on a gyrus rather than a sulcus, flooding the burr hole with saline irrigation after dural opening, limiting the time from dural opening to final DBS electrode implantation and sealing the dural defect with fibrin glue as soon as the DBS electrode was in situ and before test stimulation/and or local field potential recording. Performing surgery in a similar position to that adopted during image acquisition, with only slight head-up tilt to encourage venous drainage, may further limit shift by minimising postural movement of intracranial structures.

Dynamic impedance monitoring was performed while introducing a 1.5- or 2.2-mm diameter, blunt-tip radiofrequency (RF) electrode to the target (Leksell RF electrodes, Elekta, Stockholm). Great care was taken to avoid electrode deviation by contact with the burr hole or dural edges. A sharp tip probe would theoretically result in less brain deformation; however, the authors avoid this technique in view of the potential penetration, rather than displacement, of intraparenchymal vessels and resulting haemorrhage. After withdrawal of the RF electrode, a quadripolar DBS electrode (Model 3389 DBS lead, Medtronic®, Minneapolis) was soft-passed down the same track. The depth of implantation of the deepest electrode was controlled by placing a depth stop a defined length along the electrode shaft. In those patients undergoing surgery under local anaesthesia, symptoms were assessed for the presence of a micro-lesion introduction effect. Monopolar stimulation through the contacts of the DBS electrode was then sequentially performed to assess for additional therapeutic effect and/or the presence of side effects (~10 min per side). The electrodes were secured in place with a skull fixation device (Medtronic burrhole cap or Stimloc device). Immediately following implantation of the DBS leads, all patients had a stereotactic MRI scan to confirm the electrode positions before implantation of the pulse generator. The perpendicular scalar (Euclidean) distance between the intended MRI target and the actual position of the implanted electrode was calculated on the immediate postoperative stereotactic MRI for each patient. The surgery was not considered to be finished until the post-operative imaging had confirmed acceptable placement of the electrodes. Prophylactic systemic antibiotics (Cefuroxime 1.5 g) were administered intraoperatively and three more times during the following 24 h. Frame fixation and imaging took approximately 45 min with an additional 30–45 min for stereotactic calculations. The typical duration of bilateral electrode implantation was 2 h for surgery under general anaesthesia and 3 h under local anaesthesia. All adverse events were recorded immediately post-operatively and during subsequent follow-up assessments.

Follow-up
Selection of the optimal stimulation parameters was based on the acute clinical response to stimulation during the first post-operative weeks, with further adjustment of parameters as required, at follow-up visits typically at 1, 3, 6 and 12 months. To ensure optimal stimulation parameters, all patients underwent off- and on-medication assessments at their 6–12 months post-operative visit and then annually thereafter, using the UPDRS scale. Patients completed post-operative PDQ39 quality-of-life scales and neuropsychological assessments at their 6–12-month follow-up visit, and follow-up evaluation of speech was performed in all patients after 2004.
Data presentation and analysis
The presentation of clinical outcome data includes the median, the mean and the range of outcomes. Comparisons of baseline and post-operative UPDRS and PDQ39 scores were performed using two-sided sign tests to avoid assumptions regarding data distribution. The motor response to DBS was calculated in two ways:

1. Percentage improvement in UPDRS III motor score from baseline to follow-up in the absence of medication=(Baseline off-med score)−(Post-operative off-med ON-stim score)/(Baseline off-med score)×100.
2. Percentage improvement in UPDRS III motor score by turning stimulation ON at follow-up assessment in the absence of medication=(Post-operative off-med, OFF-stim score)−(Post-operative off-med, ON-stim score)/(Post-operative off-med, OFF-stim score)×100.

Imputation of data was performed among eight patients who requested not to be assessed in post-operative off-med, OFF-stim condition, as equal to baseline off-medication score. Composite sub-scores were derived from the sum of items 52–34 for total dyskinesia severity.

RESULTS
Demographic data for the 79 consecutive patients are presented in table 1.

Two patients had undergone unilateral pallidotomy before their initial consultations with us. In one of the 79 patients, the procedure was abandoned because of prolonged superficial bleeding from a cortical vein, and the consequent CSF leakage resulted in brain shift away from the skull. A decision was taken not to implant the permanent electrode after haemostasis was secured. Post-operative recovery was uneventful with no evidence of haemorrhage on postoperative imaging.

The remaining patients all underwent bilateral STN DBS, 77 during the same operating session. One patient had an unplanned staged bilateral procedure because of a complex partial seizure that followed the insertion of the first electrode. Following surgery, two patients did not have follow-up assessments because of (1) encephalopathy of unknown origin (presumed to be allergic) following electrode implantation requiring removal of all DBS hardware a few days later and (2) death from previously undiagnosed asymptomatic carcinoma 9 months following surgery. The remaining 76 patients all underwent formal re-evaluation of PD severity after at least 6 months of post-operative follow-up. Where patients had multiple follow-up assessments available, data were used from the assessment closest to the first anniversary of their surgery (median 12 months, mean 14 months (range 6–36 months).

All electrodes were implanted by means of a single brain procedure and hardware related adverse events
Among this consecutive series of 79 patients, superficial bleeding from a cortical vein was encountered in one patient during surgery. Once haemostasis had been achieved, a substantial quantity of CSF had leaked from the dural opening, the brain had fallen away from the skull and a decision was taken not to implant the permanent electrode. The procedure was, therefore, abandoned. Post-operative recovery was uneventful with no new neurological deficit and no haemorrhage visible on post-procedure scan. A further patient had their electrodes removed within the first 2 weeks post-operatively due to the development of a fluctuating encephalopathy with widespread white matter signal changes bilaterally following the course of the electrodes. The remaining “surgical” adverse events are documented in table 5. One patient died from disseminated malignancy within 9 months of surgery and did not have follow-up scoring performed. Three patients underwent further surgery for their PD due to insufficient response from the first operation: re-positioning of one of the two STN electrodes in one patient with improvement in clinical effect, and additional bilateral globus pallidus internus (GPi) electrode placement in two patients more than 1 year after their STN DBS procedure.

Table 1 Demographic data of patients undergoing bilateral STN DBS

<table>
<thead>
<tr>
<th>Sex distribution</th>
<th>Median (Mean, SD, Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at surgery</td>
<td>58.9 years (57.3, 7.7, 34.5–70.2)</td>
</tr>
<tr>
<td>Duration of PD symptoms</td>
<td>11.5 years (13.4, 7.0, 3.8–42.2)</td>
</tr>
<tr>
<td>L-dopa equivalent dose</td>
<td>1620 mg per day (1620, 641, 0–3260)</td>
</tr>
<tr>
<td>First degree relative diagnosed with PD</td>
<td>12/79 (15%)</td>
</tr>
</tbody>
</table>
substantial inter-patient variability in response. SD in mean outcome, as in the current series, suggests the sensorimotor STN is thought to occupy the most superior, trajectory closer to the functional target.15 The optimal target point within the visualised STN is as yet undefined.16 Among 565 patients, an overall improvement of 54% in the UPDRS III motor subscale was 27.6 points (equivalent to 52% off-medication score at 6 months compared with baseline, equivalent to 29% improvement in scores. In addition, there was a 7.7-point improvement in the PDQ39 summary index with improvements in 7/8 sub-domains. Among this group of patients, there was one patient death from intracerebral haemorrhage following the surgery and 16 infections related to the electrodes or neurostimulator requiring removal of the hardware.

In a meta-analysis of open label studies including 21 patient populations,18 the mean improvement following STN DBS in the UPDRS motor subscale was 27.6 points (equivalent to 52% improvement from baseline), and the mean improvement in quality-of-life was 34.5%. These patients sustained intracranial haemorrhage in 5.9%, infection in 1.7% and seizures in 1.5%. In a further meta-analysis including 31 STN studies and totalling 565 patients, an overall improvement of 54% in the UPDRS III score was identified.19 The mean improvement in UPDRS III off-medication scores in the current series is thus in the average range when compared to that seen in either of the two large multi-centre trials16 17 and the meta-analyses of published data.18 19

The second large randomised controlled trial of DBS17 included 121 patients who received either STN DBS (n=60) or GPi DBS (n=61). Of note is that this trial included at least 25% of the patients aged >70 years. All 13 participating sites were selected because they used MER to help in targeting. Among the group of patients as a whole, there was a 12.3-point improvement (95% CI 14.5 to 10.8, SD not stated) in the UPDRS III off medication score at 6 months compared with baseline, equivalent to 29% improvement in scores. In addition, there was a 7.7-point improvement in the PDQ39 summary index with improvements in 7/8 sub-domains. Among this group of patients, there was one patient death from intracerebral haemorrhage following the surgery and 16 infections related to the electrodes or neurostimulator requiring removal of the hardware.

In a meta-analysis of open label studies including 21 patient populations,18 the mean improvement following STN DBS in the UPDRS motor subscale was 27.6 points (equivalent to 52% improvement from baseline), and the mean improvement in quality-of-life was 34.5%. These patients sustained intracranial haemorrhage in 5.9%, infection in 1.7% and seizures in 1.5%. In a further meta-analysis including 31 STN studies and totalling 565 patients, an overall improvement of 54% in the UPDRS III score was identified.19 The mean improvement in UPDRS III off-medication scores in the current series is thus in the average range when compared to that seen in either of the two large multi-centre trials16 17 and the meta-analyses of published data.18 19

### DISCUSSION

To the best of our knowledge, this is the largest published series of STN DBS performed in a single centre. Baseline patient demographics in the present study are similar to those operated in other series in terms of severity and duration of disease.15–18 Median overall improvement from baseline in the UPDRS III off-medication motor score was 56% (mean 52%) and median improvement in PDQ39 Summary index was 7.9 points (mean 5.5 points). The low morbidity of the MRI-guided approach to surgery employed in this series demonstrates a high standard of safety while maintaining therapeutic efficacy.

There have been two large randomised controlled trials that evaluated the outcomes following DBS surgery in comparison to best medical treatment, one involving patients with STN DBS16 and the other with patients having DBS in either the STN or GPi.17 Among 78 patients with STN DBS aged <75 years, there was a mean improvement in the off-medication UPDRS III motor score of 19.6 points (15.1), equivalent to a 41% improvement, comparing baseline to post operative scores at 6 months.16 In parallel with this there was a 9.5-point (15.3) improvement in the PDQ39 summary index, equivalent to an overall mean improvement of 25% at 6 months, which is broadly similar to the overall mean improvement of 18% (median improvement 23.5%) in our patients after 1 year of follow-up. This trial was conducted across 10 centres in Germany with STN targeting using either stereotactic MRI, ventriculography, MER or a combination of these techniques according to local surgical protocols. Adverse events in this series included one death from an intra-cerebral haemotoma, one suicide 5 months after surgery and two infections at the stimulator site. The mean improvements in the clinical outcomes confirm the overall efficacy of the technique, although the wide SD in mean outcome, as in the current series, suggests substantial inter-patient variability in response.
Table 3  Comparison of UPDRS part IV sub-scores pre-operatively and post-operatively

<table>
<thead>
<tr>
<th>UPDRS IV</th>
<th>Baseline Mean (SD)</th>
<th>Follow-up (ON stim) Mean (SD)</th>
<th>Improvement from baseline to follow-up</th>
<th>Median Range</th>
<th>Mean (SD) Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dyskinesia</td>
<td>1.49 (0.85)</td>
<td>0.81 (0.84)</td>
<td>0.68 (0.9)</td>
<td>0.65 (1.2)</td>
<td>0.47 (0.81)</td>
</tr>
<tr>
<td>Pain</td>
<td>0.55 (0.93)</td>
<td>0.32 (0.72)</td>
<td>0.23 (1.2)</td>
<td>0.65 (1.2)</td>
<td>0.47 (0.81)</td>
</tr>
<tr>
<td>Early morning dystonia</td>
<td>No=35</td>
<td>No=46</td>
<td>Improved=19</td>
<td>Unchanged=35</td>
<td>Worsened=8</td>
</tr>
<tr>
<td>Predictable ‘offs’</td>
<td>No=4</td>
<td>No=37</td>
<td>Improved=24</td>
<td>Unchanged=35</td>
<td>Worsened=8</td>
</tr>
<tr>
<td>Unpredictable ‘offs’</td>
<td>No=22</td>
<td>No=57</td>
<td>Improved=26</td>
<td>Unchanged=42</td>
<td>Worsened=8</td>
</tr>
<tr>
<td>Sudden “offs”</td>
<td>No=34</td>
<td>No=62</td>
<td>Improved=19</td>
<td>Unchanged=35</td>
<td>Worsened=8</td>
</tr>
<tr>
<td>Proportion time off</td>
<td>1.82 (0.72)</td>
<td>0.77 (0.81)</td>
<td>0.43 (0.8)</td>
<td>0.65 (1.2)</td>
<td>0.47 (0.81)</td>
</tr>
</tbody>
</table>

Post-operative MRI confirmation of electrode location confirms the reliability of MRI-guided electrode placement without MER. There is paucity of publications that report on outcome of STN DBS using image-guided techniques. Our data demonstrate that MER may not be a pre-requisite to ensure well-placed electrodes that deliver a satisfactory clinical outcome. Importantly, the adverse event profile seen in this series compares very favourably with that reported in neuro-surgical series that used MER, with no infection, haemorrhage or mortality associated with surgery, in the current series. The risk of symptomatic haemorrhage inevitably rises with increasing numbers of micro- or macro-electrode brain penetrations. Furthermore, since MER significantly prolongs the procedure, we have been concerned that this potentially increases the risk of brain shift due to CSF leakage, which may paradoxically lower the precision of electrode placement as well as potentially increasing the risk of infection.

None of the patients in this series had visible haemorrhage on post-operative imaging. The single patient that suffered a pulmonary embolus was treated with a vena cava filter, made a complete recovery and has an excellent response to DBS. Of the two patients that had peri-operative seizures, one had a history of previous seizures and the other did not. Neither patient is on long-term antiepileptic medication or has had seizures subsequently.

The number of surgical adverse events in our patients is very low. Nevertheless, the patient that required removal of electrodes warrants further discussion. Post-implant MR images revealed edema surrounding the entire intra-cerebral course of both electrodes. This lady had no history of allergy and did not reveal any evidence of nickel allergy when subsequently tested. The early post-operative course was unremarkable for the first few days but was followed by a fluctuating encephalopathy that did not respond to oral steroids. The electrodes were removed and were negative for Gram stain and fungal culture. Subsequent management of PD symptoms has been with medical therapies alone. We are unaware of any previous publications of this type of reaction to DBS surgery.

Table 4  Comparison of PDQ39 quality of life scores pre-operatively and post-operatively

<table>
<thead>
<tr>
<th>PDQ39 SI</th>
<th>Baseline Mean (SD)</th>
<th>Follow-up (ON-stim) Mean (SD)</th>
<th>Difference from baseline Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30.2 (13.0)</td>
<td>24.7 (15.0)</td>
<td>5.5 points (17.3)</td>
<td></td>
</tr>
<tr>
<td>28.2</td>
<td>23.8</td>
<td>4.6 points (17.3)</td>
<td></td>
</tr>
<tr>
<td>5.7 to 59.8</td>
<td>5.9 to 78.2</td>
<td>10.7 points (25.6)</td>
<td></td>
</tr>
</tbody>
</table>

Table 5  Adverse events arising as a result of surgery in this series

<table>
<thead>
<tr>
<th>Symptomatic haemorrhage</th>
<th>Nil</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic haemorrhage</td>
<td>Nil</td>
</tr>
<tr>
<td>Pulmonary Embolus</td>
<td>1</td>
</tr>
<tr>
<td>Misplaced electrode</td>
<td>1</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>1</td>
</tr>
<tr>
<td>Transient confusion/delirium</td>
<td>1</td>
</tr>
<tr>
<td>Seizure</td>
<td>2</td>
</tr>
<tr>
<td>Suicide</td>
<td>Nil</td>
</tr>
<tr>
<td>Scalp erosion</td>
<td>1</td>
</tr>
<tr>
<td>Infection</td>
<td>Nil</td>
</tr>
<tr>
<td>DBS Malfunction</td>
<td>Nil</td>
</tr>
<tr>
<td>Lead fracture</td>
<td>Nil</td>
</tr>
<tr>
<td>Lead migration</td>
<td>Nil</td>
</tr>
</tbody>
</table>

Research paper
Several patients in our series developed dysarthria limiting stimulation settings to those that provide more modest motor improvements. Outcome measures of improvement in motor disability using “optimal” stimulation parameters are thus also influenced by other confounders. In a previous analysis of speech outcomes following STN DBS, we have reported that speech intelligibility deteriorates with stimulation among patients with electrodes situated in a more medial position.5 We, therefore, advocate imaging strategies that may further reduce the observed targeting error and improve reproducibility of electrode location with respect to the individual radiological anatomy.

This series confirms that MRI-guided STN DBS can lead to substantial mean improvements in motor disability of PD patients with improvement in quality of life. Reducing the risk associated with surgery through meticulous patient selection and optimal practice should serve as reassurance to patients with PD who may stand to benefit from this intervention but remain appropriately cautious about taking risks with their health.

Acknowledgements This work was supported by the Parkinson’s Appeal registered charity 283084. The work was undertaken at UCLH/UCL who received a proportion of funding from the UK Department of Health’s NIHR Biomedical Research Centres funding scheme.

Funding Other funders: Parkinson’s Appeal.

Competing interests The authors have no competing interests in the publication of this article.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

MRI-guided STN DBS in Parkinson's disease without microelectrode recording: efficacy and safety

T Foltynie, L Zrinzo, I Martinez-Torres, E Tripoliti, E Petersen, E Holl, I Aviles-Olmos, M Jahanshahi, M Hariz and P Limousin

J Neurol Neurosurg Psychiatry 2011 82: 358-363 originally published online June 22, 2010
doi: 10.1136/jnnp.2010.205542

Updated information and services can be found at:
http://jnnp.bmj.com/content/82/4/358

These include:
References
This article cites 29 articles, 4 of which you can access for free at:
http://jnnp.bmj.com/content/82/4/358#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Editor's choice (136)
Drugs: CNS (not psychiatric) (1945)
Parkinson's disease (690)
Pain (neurology) (763)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/